908111-35-3

Basic information

• Product Name: 2-bromo-4-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)benzonitrile
• Synonyms: 2-bromo-4-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)benzonitrile
• CAS NO: 908111-35-3
• Molecular Weight: 412.209
• Mol File: 908111-35-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2-bromo-4-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)benzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-4-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)benzonitrile(908111-35-3)
• EPA Substance Registry System: 2-bromo-4-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)benzonitrile(908111-35-3)

Safety Data

• Hazardous Substances Data: 908111-35-3(Hazardous Substances Data)

Upstream product

• 126-81-8 dimedone 
• 41189-09-7 (E)-N'-(3,3-dimethyl-5-oxocyclohexylidene)-4-methylbenzenesulfonohydrazide 
• 908111-34-2 6,6-dimethyl-3-(trifluoromethyl)-1,5,6,7-tetrahydro-4H-indazol-4-one 
• 36282-26-5 2-bromo-4-fluorobenzonitrile 

Downstream Products

• 908112-43-6 SNX-2112 
• 1073973-47-3 C₂₉H₂₉F₃N₄O₂ 
• 1073973-37-1 (S)-3-[2-Cyano-5-(6,6-dimethyl-4-oxo-3-trifluoromethyl-4,5,6,7-tetrahydro-indazol-1-yl)-phenylamino]-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1073973-40-6 4-(6,6-dimethyl-4-oxo-3-trifluoromethyl-4,5,6,7-tetrahydroindazol-1-yl)-2-((R)-2-hydroxy-propylamino)-benzonitrile 
• 1073973-30-4 3-[2-cyano-5-(6,6-dimethyl-4-oxo-3-trifluoromethyl-4,5,6,7-tetrahydro-indazol-1-yl)-phenylamino]-(S)-piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

COMBINATION THERAPY FOR TREATING CANCER

A method of treating cancer comprising administering an effective amount of each of a chemotherapeutic agent and an Hsp90 inhibitor, either separately or as a covalent conjugate of the two, to provide a combination therapy having an enhanced therapeutic e

Design, synthesis, and evaluation of small molecule Hsp90 probes

A number of compounds from different chemical classes are known to bind competitively to the ATP-pocket of Hsp90 and inhibit its chaperone function. The natural product geldanamycin was the first reported inhibitor of Hsp90 and since then synthetic inhibitors from purine, isoxazole and indazol-4-one chemical classes have been discovered and are currently or soon to be in clinical trials for the treatment of cancer. In spite of a similar binding mode to Hsp90, distinct biological profiles were demonstrated among these molecules, both in vitro and in vivo. To better understand the molecular basis for these dissimilarities, we report here the synthesis of chemical tools for three Hsp90 inhibitor classes. These agents will be useful for probing tumor-by-tumor the Hsp90 complexes isolated by specific inhibitors. Such information will lead to better understanding of tumor specific molecular markers to aid in their clinical development. It will also help to elucidate the molecular basis for the biological differences observed among Hsp90 inhibitors.

TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES

Disclosed are compounds and pharmaceutically acceptable salts of Formula (I): wherein R1, R2, R3, R4, R5, R6, R7, n, Q1, Q2, Q3, Y, and X1-X4 are as defined